Shanghai ZhenGe Biotechnology Co.,Ltd. announced that it has received $100,000,000 in its series C round of funding co-led by new investors Goldman Sachs Asset Management, L.P., Sofina Société Anonyme and Novo Holdings A/S on January 11, 2022. The transaction included participation from returning investors Shenzhen Co-win Venture Capital Investments Limited, IDG Capital Partners Co., Ltd., Lyfe Capital, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, and Junxin (Shanghai) Equity Investment Fund Management Co., Ltd. As a part of the transaction, Kevin Xu, Managing Director at Goldman Sachs Asset Management, L.P., has joined the company's board of directors. The company has raised $225,000,000 in funding till date.